McDermott + Bull has successfully placed Dr. Susan Daniels as Chief Scientific Officer at Avellino Labs. In her new role, Susan will work with the company’s Founder and Chairman to set the scientific direction of the company in developing new diagnostic tools and therapies for patients affected by a multitude of conditions through the science of genetics and gene modification. She will oversee the Global Research and Development and Quality Assurance teams as Avellino continues to expand, playing an integral role in Avellino ‘s evolution from an ophthalmology-based genomics company to a global genomics powerhouse.
With a deep background in commercialization, business development, research chemistry, and bioinformatics as well as a PhD in genetics and sequencing, Susan brings amazing capability to the team at Avellino as they move into their next phase of development as a company at the core of genetic data discovery. Her past work as a founding member of CardioDx, and later at Roche Molecular Systems and IDbyDNA, will be invaluable as she leads the science forward at Avellino.
Avellino is building a world-class platform for the effective and rapid analysis of genes associated with important medical conditions. It was the first lab in the United States performing commercial genetic testing for Corneal Dystrophy. Their advanced genetic diagnostics systems provide fast, safe, and affordable evaluations of an individual’s genetic predisposition for specific medical conditions.
This executive search was completed by McDermott + Bull Partner Jake Vander Zanden, Director Jessica Combs, and Research Manager Rachel Terry Simonsen.